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Detailed metabolic proﬁling in large-scale epidemiologic studies has uncovered novel biomarkers for cardiome-
tabolic diseases and clariﬁed the molecular associations of established risk factors. A quantitative metabolomics
platform based on nuclear magnetic resonance spectroscopy has found widespread use, already proﬁling over
400,000 blood samples. Over 200 metabolic measures are quantiﬁed per sample; in addition to many biomarkers
routinely used in epidemiology, the method simultaneously provides ﬁne-grained lipoprotein subclass proﬁling and
quantiﬁcation of circulating fatty acids, amino acids, gluconeogenesis-related metabolites, and many other mole-
cules from multiple metabolic pathways. Here we focus on applications of magnetic resonance metabolomics for
quantifying circulating biomarkers in large-scale epidemiology. We highlight the molecular characterization of risk
factors, use of Mendelian randomization, and the key issues of study design and analyses of metabolic proﬁling for
epidemiology. We also detail how integration of metabolic proﬁling data with genetics can enhance drug develop-
ment. We discuss why quantitative metabolic proﬁling is becoming widespread in epidemiology and biobanking.
Although large-scale applications of metabolic proﬁling are still novel, it seems likely that comprehensive biomarker
data will contribute to etiologic understanding of various diseases and abilities to predict disease risks, with the
potential to translate into multiple clinical settings.
amino acids; biomarkers; drug development; fatty acids; Mendelian randomization; metabolomics; nuclear
magnetic resonance; serum
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase;
LDL, low-density lipoprotein; MS,mass spectrometry; NMR, nuclear magnetic resonance.
Omics proﬁling—genomics, epigenetics, proteomics, and
metabolomics—is becoming increasingly widespread in the
worldwide efforts to prevent noncommunicable diseases. This
is driven by the quest for better etiologic understanding but
also importantly by technical developments that allow quanti-
tative high-throughput methodologies for several -omics, notably
genome-wide single nucleotide polymorphisms (1, 2), genome-
wide DNA methylation (3, 4), and detailed metabolic proﬁling
(5–14). Advancements in the experimental throughput ofmetabo-
lomics have paved the way for applications in large-scale epide-
miologic studies, and the utility of metabolic proﬁling to advance
our understanding of disease etiologies and to improve risk
predictions is becoming apparent (5, 15–18). The simultaneous
quantiﬁcation of circulating biomarkers acrossmultiple pathways
gives a ﬁne-grained snapshot of a person’s metabolic state and
offers molecular insights on health and disease. Recent advance-
ments in experimental throughput have paved the way for wide-
spread applications of metabolic proﬁling in population cohorts,
with an initial focus on the etiology and biomarkers of cardiome-
tabolic diseases (5–7, 19–24).
General aspects of design and analysis of metabolomics
studies in epidemiologic research has recently been reviewed
in this journal (20). In this review, we focus on large-scale
epidemiologic applications of nuclear magnetic resonance
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(NMR) metabolomics for quantifying circulating biomarkers.
The emphasis is on a speciﬁc platform for quantitative high-
throughput serum metabolomics, because this is the ﬁrst, and
currently the only, NMR-based metabolomics platform broadly
applied in large-scale epidemiologic studies (5). We start out by
covering the overall characteristics of this platform. We also
detail how integration of metabolic proﬁling data with genetics
can enhance drug development, and we provide some reﬂec-
tions on study design and statistical analyses based on lessons
learned from various applications of metabolic proﬁling in large
cohort studies.
FROMLIPOPROTEINQUANTIFICATION TO
COMPREHENSIVEMETABOLIC PROFILING
A high-throughput NMR platform for epidemiologic
applications
NMR-based lipoprotein quantiﬁcation has a long history
(22, 25, 26). During the past decade, our research team has
focused on the development of a quantitative NMR metabo-
lomics platform for high-throughput proﬁling of serum (and
plasma) samples, in which the lipoprotein quantiﬁcation has
been taken to subclass level, and the metabolic quantiﬁcations
extended broadly beyond lipoproteins (5, 23). The development
has been made from the initial phase with applications in epide-
miology and clinical settings in mind. This focus has directed
experimental optimization for absolute quantiﬁcation, maximal
throughput, and cost-effectiveness.
In addition to analyses of lipoprotein measures, recently
extensively reviewed by Mallol et al. (25), NMR spectroscopy
can also be used as a general method to quantifymultiple molec-
ular constituents in serum and other bioﬂuids (27–29). However,
with the exception of studies using the NMRmetabolomics plat-
form described in this review, very few applications of NMR for
quantifying a broad spectrum of circulating metabolites have
been published in epidemiologic contexts (5, 29, 30). Thus, the
situation in the ﬁeld is currently such that the large-scale applica-
tions of serum NMR metabolomics (summarized in Table 1)
include only studies based on the platform in question.
An overview of the metabolic biomarkers quantiﬁed by the
high-throughput serum NMR platform is shown in Web Fig-
ure 1 (available at https://academic.oup.com/aje). A multitude
of metabolic measures is quantiﬁed directly from serum in a
single experiment. The proﬁling covers both standard lipid
measures and a wealth of other metabolic biomarkers. In con-
trast to other NMR methodologies of advanced lipoprotein
proﬁling (25, 31–33), this platform also provides quantiﬁcation
of many fatty-acid measures, some abundant proteins, and a
broad range of low-molecular-weight metabolites together
with very detailed lipoprotein subclass proﬁling (5). The panel
of biomarkers has not been preselected based on anticipated
biological relevance, but the metabolic measures are included
because it is feasible to quantify these measures robustly in a
single experiment (23). Circulating metabolites at concentra-
tions down to ≈10 μmol/L are quantiﬁed, but the exact limit
depends on the molecular identity. The biomarker output pro-
vided contains the majority of the metabolic information reli-
ably quantiﬁable by NMR spectroscopy of serum (5, 23).
Even with a substantial increase in the measurement time
(at the expense of cost-effectiveness), only a fewmeasures could
be added to the biomarker panel. The experimental capacity is
linearly scalable, dependent only on the number of spectro-
meters. The pricing for the entire biomarker panel is compa-
rable to that of the more restricted lipid testing by routine
clinical chemistry methods (5).
In the case of the NMR metabolomics platform discussed
here, over 200 biochemically and metabolically distinct mea-
sures are given as the standard output (Web Figure 1). This
number includes around 150 primary concentrations as well as
selected ratios. For instance, individual fatty-acid concentrations
relative to total fatty acids are included because they better
reﬂect the biology of individual fatty acids than do the absolute
concentrations (34), and the ratios are commonly the onlymetric
captured by complementary analytic methods (35). The lipid
composition measures of lipoprotein subclass particles are also
included in the overall number of metabolic measures because
they deﬁne a biologically separate entity of measures (36).
Sample preparation
The blood samples routinely collected in epidemiologic co-
horts and biobanks can be directly used for metabolic proﬁling.
In general, any collection of blood samples amenable for lipid
testing by standardmethods can be used for the NMR platform.
This means that samples stored long-term must have been kept
at a temperature of −70°C or colder to retain the composition
of lipoprotein particles, and the integrity of other metabolic
measures. Both fasting and nonfasting samples can be analyzed
(5, 37). The spectral characteristics of serum samples reﬂect vari-
ous aspects of sample quality, and quality-control procedures
can detect irregularities due to potential sample degradation.
A sample volume of either 100 μL or 350 μL is used for the
analysis, with both volumes yielding the same set of metabolic
measures; analyses with the larger volume are more cost-effective
due to shorter measurement time in the NMR spectrometer.
One of the primary advantages of NMR is the minimal sample
preparation required. Automated liquid handlers simply mix a
buffer with the serum and move the material to 96-format racks
of NMR tubes. The racks are subsequently inserted into the
robotic sample changer, cooled to refrigerator temperature.
The sample changer holds 480 samples simultaneously, yielding
over 24 hours of automated measurements before the need to
reload more samples. Automated shimming, accurate temperature
control, and stable electronics in modern off-the-shelf NMR spec-
trometers have been a prerequisite for the high throughput. Details
of the present platform have been described previously (5, 23).
The original methodology was based on 3 molecular windows,
of which 2 were acquired from the original serum samples, and 1
from the serum lipid extracts (23, 38, 39).More recently, a faster
method has been developed in which the computational analysis
circumvents the need for experimental lipid extractions.
In NMR spectroscopy, absolute quantiﬁcation of metabolic
measures in absolute units, rather than relative to another mea-
sure, can currently be achieved without external standards added
to the blood specimen (40). In the NMRmetabolomics platform
that is the focus of this review, advanced proprietary software
with integrated quality control is used to convert the spectral
information to absolute concentrations of the metabolic mea-
sures. The basis for the metabolite quantiﬁcation is Bayesian
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Table 1. Metabolic Proﬁling Studies That Had>5,000 Participants and That UsedQuantitative SerumNuclear Magnetic Resonance
Metabolomics
Focus Study Populations and Description Reference(s)
Biomarkers for Disease Events and Risk Prediction
Cardiovascular disease Biomarker discovery for risk of ﬁrst incident cardiovascular event (n = 13,441 Finns and
Britons from 3 population-based studies with 12–23 years of follow-up). Phenylalanine
andMUFAswere found to be predictive of higher CVD event risk, whereas omega-6
fatty acids and docosahexaenoic acid levels were inversely associated with CVD
event risk, after adjustment for routine lipid levels and other risk factors. These 4
biomarkers in combination improved risk reclassiﬁcation above established risk
factors in 2 validation cohorts. Analytic and biological comparison of biomarkers
quantiﬁed by the NMR platform and 2MS platforms (n > 2,000 Americans and n >
2,000 Finns in the analytic and biological comparison between NMR andMS
biomarker associations).
7
All-causemortality Discovery and replication of biomarkers for 5-year risk of death. Glycoprotein
acetylation, albumin, VLDL particle size, and citrate were found to be strongly
predictive of the short-term risk of all-causemortality, and a biomarker score was
shown to improve risk prediction and illustrate a potential clinical application for patient
prioritization (n = 17,345 Estonians and Finns from 2 population-based studies).
37
Inﬂammation Molecular etiology of glycoprotein acetylation, the strongest biomarker for all-cause
mortality identiﬁed in Fischer et al. (37), investigated by cytokine panels and whole
blood gene expression networks. Glycoprotein acetylation was found to be amarker of
chronic inﬂammation related to increased neutrophil activity and strongly predictive of
the long-term risk for sepsis and respiratory infections (n ≈ 10,000 Finns from 3
population-based cohorts).
16
Type 2 diabetesmellitus Cross-sectional associations of 8 amino acids with glycemia (n ≈ 9,400 Finnishmen)
and risk for onset of type 2 diabetes (n = 526). Branched-chained and aromatic amino
acids, as well as alanine and glutamine, were predictive of diabetes risk, partly
explained by insulin resistance.
34, 36, 42, 43, 90
Cross-sectional and prospective associations of the ketones acetoacetate and β-
hydroxybutyrate (n ≈ 9,400 Finnish men/n ≈ 4,300 in prospective analyses), showing
positive association with future glucose tolerance and, in the case of acetoacetate,
higher risk for diabetes onset. The results were attributed to insulin sensitivity rather
than insulin resistance.
56
Associations of fatty acids with 5-year glucose tolerance and type 2 diabetes risk (n ≈
9,400 Finnishmen/n ≈ 4,300 in prospective analyses), showing that glycerol,
triglycerides, andMUFAs are positively associated with diabetes risk, and omega-6
fatty acids are inversely associated.
34
Prospective associations of lipids and lipoprotein subclassmeasures with glycemia and
type 2 diabetes risk (n ≈ 6,607 Finnishmen), showing stronger predictive associations
of lipoprotein and apolipoprotein ratios than routine lipid measures.
78
Metabolic Risk-Factor Characterization
Adiposity Mendelian randomization analyses of bodymass index as a causal risk factor for
systemicmetabolism: causal effects of adiposity on numerousmetabolicmeasures,
including branched-chain and aromatic amino acids, omega-6 fatty acids, and
glycoprotein acetylation aswell asmultiple lipoprotein lipid subclasses and particle size
measures (n = 12,664 young adults from4 population-based cohorts in Finland).Weight
changeswere paralleled by extensivemetabolic changes, with a similar metabolic
signature as observed cross-sectionally and genetically (n ≈ 1,500with 3 time points).
8
Insulin resistance Cross-sectional associations of metabolites with insulin resistance index (n = 7,098
young Finnish adults from 2 population-based cohorts in Finland). Results showed
numerous strongmetabolite associations with insulin resistance, independent of
components of the metabolic syndrome, and uncoveredmultiple sex-speciﬁc
associations and adiposity interactions.
21
Cross-sectional associations of lipoprotein subclassmeasures with different indices for
insulin resistance, showingmore prominent associations with liver insulin resistance
than with whole-body insulin sensitivity (n = 8,750 Finnish men).
91
Cross-sectional associations of lipoprotein subclass proﬁles with glucose tolerance
categories and insulin resistance index, showing prominent associations of insulin
sensitivity with VLDL and HDL subclasses, including heterogenic associations for
small HDL (n = 9,400 Finnishmen).
36
Sex hormone–binding globulin Mendelian randomization analysis indicating that sex hormone–binding globulin is
strongly associated with numerous circulatingmetabolites but not a causal risk factor
for the systemicmetabolic effects (n ≈ 16,000 from 4 Finnish cohorts for either cross-
sectional or causality analyses).
74
Birth weight Associations of lower birth weight with themetabolic proﬁle in adolescents and adults.
Themetabolic associations found were of modest magnitude and displayed a similar
overall metabolic signature as themetabolite association pattern with higher adiposity
(n = 18,288 from 7 population-based cohorts from Finland and the United Kingdom).
73
Table continues
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Table 1. Continued
Focus Study Populations and Description Reference(s)
Menopause and aging Associations of age, sex, andmenopause with the systemicmetabolic proﬁle, assessed
cross-sectionally (n ≈ 23,000 people from 8 cohorts in Finland and Estonia).
Menopause status was associated with glutamine, tyrosine, and isoleucine, along with
atherogenic lipoprotein measures.
92
Alcohol consumption Cross-sectional associations of alcohol consumption with the systemicmetabolic proﬁle
(n = 9,778 young Finnish adults from 3 population-based cohorts). Results showed
robust biomarkers for alcohol intake beyond routine lipids, including adverse
associations with omega-6 fatty acids, MUFAs, glutamine, and citrate. Longitudinal
analyses showed that the metabolic signature of alcohol intake track with changes in
alcohol intake (n ≈ 1,450 with 3 time points).
93
Vitamin D Cross-sectional associations of serum25-hydroxyvitamin D concentrationswith the
systemicmetabolic proﬁle (n = 1,726 in a discovery cohort and n = 6,759 in a replication
cohort). Results showed 30 replicatedmetabolic associations, including constituents of
large VLDL and small LDL subclasses and relatedmeasures such serum triglycerides, as
well as fatty acids andmeasures reﬂecting the degree of fatty acid saturation.
54
Metabolic Effects of Drug Interventions
Statin therapy Effects of statins on the systemicmetabolic proﬁle, assessed for 4 longitudinal cohorts
(n = 5,590 with 2 time points). Statins were shown to lower small VLDL particles and
remnant cholesterol, in addition to the LDL-lowering effects. Minimal or no side effects
on nonlipid metabolites were observed. The observational results were validated by
Mendelian randomization analyses in 8 population-based cohorts (n = 27,914), with
associations in theHMGCR gene perfectly matching the longitudinal associations.
13
Hormonal contraceptives Effects of hormonal contraception on the systemicmetabolic proﬁle assessed in cross-
sectional and longitudinal settings (n = 5,841women from 3 Finnish cohorts; n = 869
with 2 time points). Combined oral contraceptive pills were shown to have very
prominent metabolic effects, including changes in many fatty acids and amino acids,
and predominantly related to higher cardiometabolic risk. Themetabolic aberrations
were reversed upon discontinuation. Progestin-only contraceptives had little effect on
systemicmetabolism.
75
Genome-Wide Association Studies
Genetic determinants of
circulating biomarkers
GWAS of 115metabolic measures and 99 derivedmeasures from the NMR platform.
The study identiﬁedmetabolic associations at 31 loci, including 11 novel loci (n =
8,330 individuals from 5 population-based cohorts in Finland), and provided heritability
estimates from twin pairs (n = 561 pairs; 221monozygotic and 340 dizygotic pairs).
85
GWAS of 123metabolic measures fromNMRmetabolomics (up to n = 24,925
individuals from 14 European cohorts). The study identiﬁed associations at 62 loci,
including 8 novel loci for amino acids and other metabolites. The results further
elucidated the effects of lipoprotein(a) on lipid metabolism.
30
GWAS of 11metabolic networks, identifying 34 genomic loci, of which 7 were novel. The
results illustrate howmultivariate analysis of correlatedmetabolic measures can boost
power for gene discovery (n = 6,608 from 2 Finnish cohorts).
94
Functional Genetics
Lipid genes Metabolic proﬁling and genetic ﬁne-mapping of 95 lipid loci, showing reﬁned lipid
associationswith numerous loci and illustrating howmost lipid genes affect a broad span
of lipidmeasures (n = 8,330 individuals from5 population-based cohorts in Finland).
83
Lipid genes/pleiotropy Assessment of pleiotropy in 6 cholesterol- and triglyceride-related genes. The broad lipid
association patterns indicated that the lipid loci cannot be attributed to a single routine
lipid measure, and the implications for Mendelian randomization studies are discussed
(n = 10,547 individuals from 3 population-based cohorts in Finland).
51
Type 2 diabetes genes Lipoprotein subclass proﬁling of 34 risk loci for type 2 diabetes. The results suggest that
only a small number of diabetes loci affect lipoprotein lipid measures (n = 6,580
individuals from a population-based cohort of Finnishmen).
95
Liver function genes Metabolic proﬁling of 42 genetic loci associated with concentrations of liver enzymes in
plasma, highlighting multimetabolic effects of several loci (n = 6,516 individuals from 2
population-based cohorts from Finland and the United Kingdom).
96
Blood-pressure genes Metabolic proﬁling of 29 blood pressure genes, indicating weak (if any) effects of blood
pressure on the circulatingmetabolic measures (n = 7,032 individuals from 3
population-based cohorts in Finland).
97
Interleukin-1 inhibition gene Lipoprotein subclass proﬁling of genes encoding IL-1 receptor antagonist, detailing the
proatherogenic lipid effects of IL-1 inhibition, with implications for treatment of
cardiometabolic disease by IL-1 inhibitors (n = 8,330 individuals from 5 population-
based cohorts in Finland).
76
Triglyceridemetabolism gene Metabolic proﬁling of a rare variant in APOC3, detailing the VLDL effects ofAPOC3 and
showing partly independent effects compared with the LPL gene (n = 13,285 from 2
population-based cohorts in the United Kingdom).
67
Table continues
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modeling, as described previously (5, 23, 41). The output data
for each sample comprise a list of concentrations for the meta-
bolic measures summarized inWeb Figure 1. In comparisonwith
clinical chemistry assays, theNMRmetabolomics platform essen-
tially just provides more biomarkers in a single experiment. The
accuracy of biomarker quantiﬁcation by the platform is compara-
ble to what is commonly achieved by assays routinely used in
clinical chemistry (see the caption for Web Figure 1) (30). The
consistent biomarker quantiﬁcation is due to the inherently repro-
ducible nature of NMR spectroscopy; the samples never come
into contact with the radiofrequency detector in the NMR spec-
trometer. This makes NMR metabolomics essentially free of
batch effects that commonly hamper applications of mass spec-
trometry (MS) to large-scale epidemiologic studies. Biomarker
quantiﬁcation directly from serum, without any sample extrac-
tion procedures, further contributes to the high reproducibility.
The NMR metabolomics platform featured here employs a tar-
geted approach, meaning that an a priori deﬁned set of metabo-
lites is quantiﬁed from the experimentation. The platform is
therefore not designed for novel biomarker discovery as such, in
contrast to untargeted metabolomics approaches. Nonetheless,
epidemiologic analyses based on the NMRplatform have identi-
ﬁed multiple novel and emerging biomarkers for cardiometa-
bolic diseases (5, 7, 34, 42–44), because many of the quantiﬁed
metabolic measures have not previously been studied in large
cohorts. The pros and cons of targeted versus untargeted meta-
bolomics approaches have been reviewed elsewhere (20, 45).
NMR, MS, and clinical chemistry: analytic and biological
consistency
Figure 1 shows that biomarker concentrations quantiﬁed by
the NMR metabolomics platform were highly consistent with
the concentrations obtained from routine clinical chemistry.
Figures 2 and 3 show that quantiﬁcation of emerging biomar-
kers, such as fatty acids and ketone bodies, by NMR is also
coherent with results from other analytic methods. With quan-
titative biomarker data, it does not make a fundamental differ-
ence whether a metabolic measure is quantiﬁed by NMR or by
alternative analytics—if each method identiﬁes a particular
molecular measure, only the accuracy and precision of the con-
centration measurement may differ (i.e., we do not have an
NMR-molecule, an MS-molecule, or a clinical chemistry mole-
cule but only a molecule). For applications of metabolomics in
epidemiology, consistency of metabolic biomarker associations
with disease events across different platforms is important,
maybe more so than exact analytic correspondence in absolute
concentrations. Figure 4 shows that emerging biomarkers quan-
tiﬁed by both NMR spectroscopy and 2 widely used MS plat-
forms have similar associations with disease incidence. These
results suggest that associations of amino acids and gluconeo-
genesis metabolites with cardiovascular disease (CVD) risk
are broadly consistent in their association with CVD, regard-
less of whether the biomarkers are quantiﬁed by NMR or MS.
Accordingly, associations of amino acids with the risk for type
2 diabetes mellitus have also been consistent across NMR and
MS platforms (46).
The advantages and disadvantages of NMR andMS—2 key
technologies for metabolic proﬁling—have recently been exten-
sively covered inmultiple reviews (12, 45, 47–49). These analytic
techniques offer mainly complementary insights, partly due to
their different biomarker coverage. The higher sensitivity of MS
allows for quantiﬁcation of low-concentration metabolites and
thusmore in-depth characterization of pathophysiologicalmech-
anisms (9, 50). In contrast, the cost-effectivemetabolite quantiﬁ-
cation by NMR favors large-scale epidemiologic studies, such
Table 1. Continued
Focus Study Populations and Description Reference(s)
HDLmetabolism gene Lipoprotein subclass proﬁling and genetic ﬁne-mapping ofGALNT2, a locus associated
with HDL cholesterol. Results showed themost prominent associations ofGALNT2
with cholesterol in medium-sized HDL particles (n ≈ 10,000 Finnishmen).
98
Bioinformatics Applications
Multivariate meta-analysis of
genome-wide studies
Multivariate associations of lipoprotein subclassmeasures (and genotypes), similar to
the approach used in Inouye et al. (94), but allowing analysis based on summary
statistics-based of single or multiple cohorts (n = 10,753 from 3 Finnish population-
based cohorts).
99
Multivariate gene-metabolome
associations
Bayesian reduced-rank regression to assess the impact of multiple single nucleotide
polymorphisms on a high-dimensional phenotype, demonstrated for the case of
lipoprotein subclass measures. Two novel lipid genes were identiﬁed by the
multivariate GWAS approach (n ≈ 10,000 from Finnish 3 population-based cohorts).
100
Multiple output regression with
latent noise
Study illustrating how structured noise can, and should, be taken advantage of when
assessing the associations between covariates and target variables, usingmulti-
omics data and variousmetabolic measures (n = 5,211 from 2 Finnish population-
based cohorts).
101
Network analysis integrating
genome andmetabolome
Methodology to assess differences in molecular associations and underlying genetic
variants, illustrated in the context of obesity (n = 7,255 from 2 Finnish population-
based cohorts).
102
Abbreviations: APOC3, apolipoprotein C3 gene; CVD, cardiovascular disease;GALNT2, UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-
acetylgalactosaminyltransferase 2 gene; GWAS, genome-wide association study; HDL, high-density lipoprotein;HMGCR, 3-hydroxy-3-methylglu-
taryl-coenzyme A reductase gene; LDL, low-density lipoprotein; LPL, lipoprotein lipase gene; MS, mass spectrometry; MUFA, monounsaturated
fatty acid; NMR, nuclear magnetic resonance; VLDL, very low-density lipoprotein.
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as proﬁling of entire cohorts and clinical trials (5, 7). For exam-
ple, applications of Mendelian randomization for inferring
causal relationships with genetic instruments are demanding in
terms of sample-size requirements, and therefore they beneﬁt
from the high throughput and robust quantiﬁcation offered by
NMR (5, 13, 30, 51). The possibility with NMR to quantify
biomarkers directly from serum, including standard cholesterol
and triglyceride measures, further makes the platform more
reminiscent of clinical chemistry than a technology competing
with MS. However, we consider that both metabolomics tech-
nologies have great potential in epidemiologic studies and will,
in many circumstances, complement each other. We anticipate
more applications combining NMR and MS in the near future,
particularly as cost-efﬁciency inMSmethodologies and imple-
mentations is improved (52–54).
Although the featured NMR platform is currently the only
one applied for serum metabolomics in large-scale epidemiol-
ogy, alternative high-throughput NMR setups exist for detailed
lipid analyses (25, 33, 55). In particular, the method for quan-
tifying lipoprotein particle numbers offered by LabCorp (Ra-
leigh, North Carolina) has been widely used in epidemiologic
studies as well as in clinical settings (56, 57). This approach has
recently been extended to cover quantiﬁcation of the inﬂamma-
tory biomarker glycoprotein acetylation (58, 59). This indicates
a step towards combining lipoprotein proﬁling with quantiﬁ-
cation of nonlipid biomarkers, a feature otherwise unique to
the NMR platform reviewed here. Other large-scale applica-
tions of NMR metabolomics have pertained to urine analyses
(60–62) and combination of urinary and circulating metabolite
data in genomic studies (63, 64), as reviewed previously (20).
METABOLIC PROFILING IN EPIDEMIOLOGY
Comprehensive metabolic proﬁling has recently started to
fulﬁll the promise of beneﬁts for epidemiologic research (5,
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Figure 1. Comparison of lipoprotein lipid and glucose quantiﬁcation in an epidemiologic setting, using nuclear magnetic resonance (NMR) (2013)
and routine clinical chemistry assays (y-axis) (n = 2,749 from the Avon Longitudinal Study of Children and Parents (ALSPAC) Mothers Cohort)
(103). The correlation coefﬁcients are 0.95 (A), 0.94 (B), 0.93 (C), 0.91 (D), and 0.96 (E). The lower concentration of low-density lipoprotein (LDL)
cholesterol quantiﬁed by NMR than by the Friedewald approximation stems from the latter also containing intermediate-density lipoprotein choles-
terol (104). The NMR-based LDL cholesterol refers speciﬁcally to cholesterol in the LDL particles with the sizes as deﬁned inWeb Figure 1. The cor-
respondence of these measures varies slightly from cohort to cohort, but the correspondence is generally excellent between the clinical chemistry
and the NMR for these measures. It is important to note that the comparisons illustrated here do not show strict analytic comparisons with samples
undergoing identical processing and storage time, but rather indicate analytic consistency demonstrated in epidemiologic settings. No quantitative
assessment of analytic correspondences is therefore made here. When it comes to potential clinical applications of metabolic proﬁling, more ana-
lytic and clinical testing is required, particularly with those metabolic measures that are intended to be used as part of diagnostic protocols. It is also
to be expected that ofﬁcial accreditations of analytic and laboratory procedures will be a prerequisite for widespread clinical applications. HDL,
high-density lipoprotein.
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11, 19). Although many metabolic measures are quantiﬁed
simultaneously, the same statistical methods can be used as for
other clinical chemistry assays. For instance, linear regression
modeling can be applied to each metabolic measure individu-
ally. This is useful for the initial biomarker assessment and rep-
lication, because it facilitates the biological interpretability and
enables adjustment for relevant confounders. The multivariate
statistical analyses often applied in metabolomics studies make
it difﬁcult to integrate analyses with other risk factors and relate
results to more established measures. However, analyzing the
quantitative biomarker data using standard medical statistics
makes it straightforward to combine analyses of the metabolic
biomarker panel with conventional risk factors. This can help
to put the association magnitudes of novel biomarkers into
context, and it further allows investigators to extend the analy-
ses to cover more measures than are obtained by a single meta-
bolomics platform. Nevertheless, straightforward applications
of linear regression analyses by no means preclude multivariate
or nonlinear analyses—on the contrary, quantitative molecular
data facilitate many different statistical approaches (5, 6, 65).
The NMR platform produces the full set of biomarkers for
every sample. However, once the data are obtained, investiga-
tors can report results from individual biomarkers (e.g., omega-3
fatty acids (66)), single metabolic pathways (e.g., fatty-acid bal-
ance (34)), or all the metabolic measures from the platform (67).
There are many scientiﬁc advantages in assessing the compre-
hensive biomarker data across multiple metabolic pathways. In
addition to biomarker discovery, this approach has proven to be
a powerful way to study risk factors and disease processes that
have a systemic impact on the metabolic proﬁle. For instance,
adiposity broadly affects systemic metabolism, and comprehen-
sive metabolic proﬁling therefore provides a more realistic view
on the overall molecular associations, many of which would be
missed by focusing on established risk factors or single path-
ways (8). In the case of risk prediction, it is also an asset to have
an extensive set of metabolic biomarkers at a ﬁxed cost—the
simultaneous quantiﬁcation of the routine lipid panel, glucose,
and inﬂammation along with many other emerging biomarkers
may eventually prove to be pivotal for cost-effective clinical ap-
plications (7, 13, 68).
Quantitative metabolomics data allow for hypothesis-driven
and hypothesis-free research approaches both. In the case of
biomarkers not previously investigated in large cohorts, the
hypothesis-free approach feeds hypothesis generation—if there
are no prior data on a particular biomarker, an informed hypothe-
sis is unlikely. Regardless of the analytic approach, demonstrating
replication in independent samples is important. By replication
we do not mean that separate discovery and replication cohorts
(as in Fischer et al. (37)) would be necessary. Rather, as recom-
mended for genome-wide association studies (69), joint analyses
ofmultiple independent cohorts and demonstration of consistency
(as exempliﬁed in Würtz et al. (13)) is becoming the most com-
mon approach. Regarding statistical signiﬁcance, it is important to
account for multiple testing whenever a high number of metabo-
lites are tested. A signiﬁcance threshold that accounts for multiple
testing of correlated measures can be derived by Bonferroni cor-
rection for the number of principal components explaining 95%–
99%of the variation in themetabolic data (70). For theNMRplat-
form featured in this review, this number is typically 30–50 for
each cohort, resulting in a signiﬁcance threshold of P ≈ 0.001.
However, we always advocate replication to judge the robustness
of metabolic associations rather than relying on cutpoints for sta-
tistical signiﬁcance.
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Figure 3. Comparison of circulating β-hydroxybutyrate quantiﬁcation
in an epidemiologic setting, using nuclear magnetic resonance (NMR)
and an enzymatic method (y-axis) (n = 56) (105). The correlation coefﬁ-
cient is 0.98. See note on Figure 1 for the analytic correspondence.
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Figure 2. Comparison of circulating fatty-acid quantiﬁcation in an epidemiologic setting, nuclear magnetic resonance (NMR) and gas chromatog-
raphy (y-axis) (n = 2,193 from the Cardiovascular Risk in Young Finns Study) (7). The correlation coefﬁcients are 0.92 (A), 0.94 (B), and 0.94 (C).
See note on Figure 1 for the analytic correspondence. DHA, docosahexaenoic acid; MUFA, monounsaturated fatty acid.
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OVERVIEWOF LARGE-SCALEMETABOLIC PROFILING
STUDIES BYNMR
Bymid-2016, over 400,000 blood samples from some 150 epi-
demiologic and clinical studies had been proﬁled using this NMR
platform. These include the INTERVAL study, a randomized trial
of blood donors with more than 46,000 individuals (71); the Lon-
don Life Sciences Prospective Population (LOLIPOP) study with
around 30,000 individuals (72); multiple birth cohorts and other
population-based studies with several thousand participants each;
and twin studies, as well as drug trials and other intervention stud-
ies (5).Many of the individual studies are working collaboratively
to support replication and, where appropriate, pooling of results to
obtain precise estimates and sufﬁcient power for genetic analyses.
Table 1 lists the publications to date, in which metabolic proﬁling
data on more than 5,000 people per study have been analyzed;
most of the studies includemultiple cohorts and some formof rep-
lication. In more than half the studies, the number of people with
metabolic proﬁling data is approximately 10,000 or more. The
largest study published features around 35,000 samples analyzed
(13). In the following section, we highlight two of these studies in
more detail: 1) an evaluation of the causal effects of adiposity on
systemic metabolism; and 2) an assessment of the metabolic ef-
fects of statin treatment beyond their known effects on low-
density lipoprotein (LDL) cholesterol.
Molecular characterization of adiposity
Many risk factors plausibly affect multiple molecular path-
ways, but the extent of this is largely unknown because of the
inability to study comprehensive inﬂuences on systemic metabol-
ism until recently. Determining the metabolic association patterns
across multiple pathways can also help to pinpoint similarities in
the molecular signatures of different risk factors, as in the case of
bodymass index (BMI) and birthweight (8, 73).
Our study on metabolic signatures of adiposity in 12,644
adolescents and young adults illustrates the metabolically diverse
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Figure 4. Biomarker associations with cardiovascular event risk for selected polar metabolites quantiﬁed by both nuclear magnetic resonance
(NMR) and mass spectrometry (MS). Filled squares indicate hazard ratios for incident cardiovascular disease, adjusted for age and sex, for 13,441
individuals (1,741 events) proﬁled by NMR. Open squares show the same biomarker associations in the FraminghamOffspring Study (2,289 indivi-
duals and 466 events) proﬁled by MS. Circles indicate the biomarker associations compared for the same subset of 679 individuals (305 events)
proﬁled both by NMR (ﬁlled circles) andMS (open circles). The ﬁgure is adapted fromWürtz et al. (7). CI, conﬁdence interval; HR, hazard ratio.
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effects of BMI (8). BMI was robustly associated cross-sectionally
with numerous metabolic biomarkers, as illustrated for selected
measures inWeb Figure 2. In addition to cross-sectional associa-
tions,Mendelian randomization (use of genetic instrumental vari-
ables), suggested that BMI had causal effects on multiple
metabolic pathways, including atherogenic lipoproteins and
lipids, fatty acids, and amino acids (Web Figure 2). The effect of
adiposity on systolic blood pressure illustrates the possibility
of combining the metabolic data with traditional risk markers.
Having adequate power to conduct Mendelian randomization
is a beneﬁt of quantitative metabolic proﬁling in large cohorts
(5, 74).
The overall patterns of metabolic associations were similar
for cross-sectional and causal estimates. To summarize the
causal inﬂuences of adiposity across the comprehensive meta-
bolic proﬁle, we charted all causal effect estimates against the
corresponding cross-sectional associations (Web Figure 2).
The close resemblance indicated that the associations between
BMI and circulating biomarkers are likely to reﬂect the molec-
ular effects of adiposity rather than arising from confounding
or reverse causality. Although the effects of adiposity on each
individual biomarker are modest, the overall metabolic aberra-
tions may have considerable effects on cardiometabolic risk.
Thus, the importance of excess adiposity likely arises from
multiple metabolic pathways rather than pertaining to individ-
ual risk markers. The linear character of the metabolic associa-
tions and the Mendelian randomization analyses further suggest
that there is no BMI threshold at which its adverse metabolic
effects notably increase. However, analyses ofmetabolic changes
during 6-year follow-up, in a subset of 1,466 young adults,
demonstrated that the metabolic proﬁle is highly responsive to
changes in BMI with changes congruent with expectation from
the results from cross-sectional and Mendelian randomization
analyses (8).
Combiningmetabolic proﬁling and genetic data for
exploring drug effects
Metabolic proﬁling of clinical trial samples can be an im-
portant resource to assess risk prediction in speciﬁc patient
groups as well as to provide improved understanding of the
molecular effects of interventions. By exploiting various epi-
demiologic study designs, it may be possible to estimate the
metabolic effects of certain drugs even when randomized evi-
dence is not available. For instance, this can be done by examin-
ing the metabolic changes associated with starting and stopping
the pharmacological treatment in longitudinal studies of obser-
vational cohorts, as we have recently demonstrated with statins
(13) and hormonal contraception (75). The detailed metabolic
effects can in some circumstances be assessed already at the
preclinical stage based on genetic variants mimicking the
pharmacological action of the drug targets (i.e., usingMendelian
randomization) (30, 51, 76). This approach circumvents con-
founding by indication and other biases inherent in observational
studies, although it may be biased by violation of the assumptions
of instrumental variables (77–79). In a proof-of-concept study,
we combined these 2 approaches to demonstrate how metabolic
proﬁling in observational cohorts can be used to characterize com-
prehensive metabolic effects of statin therapy (13). The character-
istics of the approach are shown inWeb Figure 3.
Statins reduce LDL cholesterol concentration by inhibiting 3-
hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR),
leading to a proportionate reduction in CVD risk. Statins have
been ascribedmyriads of pleiotropic properties beyond lowering
LDL cholesterol, yet the effects on many lipids and other bio-
markers have not been assessed in large studies, primarily due to
lack of affordable means. Because no randomized trial data on
themetabolic biomarkers were available in our proof-of-concept
study (13), the detailed metabolic effects of statins were ana-
lyzed from serially collected blood samples, in which a subset of
individuals started statin therapy during follow-up. These longi-
tudinal analyses were replicated across 4 cohorts, with consistent
results despite differences in demographics and follow-up dura-
tion. Starting statin therapy was associated with changes in
numerous lipid measures in addition to the anticipated lower-
ing of LDL. Of particular interest was a discordance between
the modest lowering of total triglycerides and an efﬁcacious
lowering of cholesterol in the very-low-density lipoprotein and
intermediate-density lipoprotein particles (i.e., the so-called rem-
nant cholesterol that has been identiﬁed as a potential causal cul-
prit in the development of ischemic heart disease) (80, 81). The
detailed metabolic proﬁling suggested that statins are more effec-
tive in reducing remnant cholesterol than previously appreciated;
this indicates potential cardioprotective beneﬁts of statins beyond
LDL-cholesterol lowering. Statin use was not robustly associated
with changes in any of the nonlipid metabolites assayed by the
platform. These results suggest no substantial side effects of
statins on, for example, circulating amino acids. However, larger
studies or randomized trials are required to demonstrate potential
minor effects on the nonlipid biomarkers, such as glycemic
effects of statins (82).
To verify that the observed metabolic changes were
actually due to the effects of statins, the analyses were cor-
roborated via Mendelian randomization by using a genetic
variant in the HMGCR gene as an unconfounded proxy for
the pharmacological action of statins. Speciﬁcally, we exam-
ined the metabolic effects of genetically induced HMGCR
inhibition—mimicking a very small statin dose—and com-
pared the metabolic association pattern with HMGCR geno-
types to the metabolic changes observed longitudinally. We
found striking concordance between the observational effects
of statins on the metabolic proﬁle and the corresponding asso-
ciations with the genetic variant inHMGCR.
The combination of metabolomics data with genetic data in a
large number of individuals readily extends beyond studying
statin effects. This type of Mendelian-randomization study
design can be seen as a “natural” clinical trial (14). Due to
the prohibitively high costs of randomized trials, it is of great
interest to assess the detailed metabolic effects of novel tar-
gets already in preclinical stages of drug development. Many
known and novel drug targets have established genetic prox-
ies mimicking their pharmacological actions, which enables
examination of the detailed metabolic association patterns of
these targets. We have previously published the metabolic
associations of genetic variants in the proprotein convertase
subtilisin/kexin type 9 and other lipid genes (5, 51, 83). With
the genome-wide association summary statistics publicly avail-
able for 123 metabolic measures (30), the ﬁne-grained met-
abolic signature related to numerous genetic targets can easily be
assessed. As extensive metabolomics and genetic data become
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increasingly available, we expect that comprehensive metabolic
proﬁles of drug targets will augment drug development in preclin-
ical stages to elucidatemolecularmechanisms and clarify pleiotro-
pic effects. It may be particularly helpful to use this type of
approach to predict whether it would be worth moving forward to
large-scale trials.
FUTURE PROSPECTS
The studies summarized in Table 1 show some of the poten-
tial value of having quantitative metabolomics data in large
epidemiologic studies. In the future, we anticipate further inte-
gration of metabolic proﬁling with genetics and other -omics
data in large epidemiologic studies. Genome-wide studies on
metabolic traits have so far primarily clariﬁed the genetic basis
of systemic metabolism (11, 30, 84, 85). The increasing collec-
tions of large-scale metabolic proﬁling with genetics will, via
Mendelian randomization, further help to establish causality of
the biomarkers as molecular intermediates between lifestyle
exposures and diseases (86, 87). Detailed lipoprotein subclass
proﬁling in combination with genetics and clinical trials are
likely to be important for uncovering the mechanisms under-
pinning how triglyceride-rich lipoproteins relate to CVD risk
(80, 88) and clarifying the elusive role of high-density lipopro-
tein in CVD (80, 89).With the linkage of metabolomics data to
health-care records, under appropriate ethical and governance
frameworks, the potential value of these new quantitative bio-
markers could be explored in real-time public health applica-
tions. In the near future, alongside continued improvements in
throughput and cost-effectiveness, we also look forward to en-
deavors of multi-omics studies on population cohorts and bio-
banks with over a million individuals.
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